Dr. Reddy's and MediCane launch medical cannabis products in Germany
Germany forms more than half of the EU’s medical cannabis market
Dr. Reddy's Laboratories and MediCane Health have joined forces to launch medical cannabis products in Germany.
As part of the collaboration, which began last year, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support. Dr. Reddy’s will be the exclusive distributor of the products in Germany.
The launch marks MediCane’s entry into the pharmaceutical sector of a major European market, while reinforcing Dr. Reddy's presence in Germany’s growing medical cannabis market. This comes after Dr. Reddy's recent acquisition of Nimbus Health GmbH, which specializes in the distribution, registration, sales and marketing of medical cannabis.
Medical cannabis was legalised in Germany in 2017 and the country now represents more than half of the European Union medical cannabis market, in large part due to developed regulations and reimbursement from sick funds under certain circumstances. According to market intelligence firm Prohibition Partners, insurance companies reimbursed around 60% of medical cannabis prescriptions in 2019.
The demand for medical cannabis has been increasing over recent years and the market in Germany is now valued at €122 million with 25% growth between 2020 and 2021. Around 150,000 German patients use medical cannabis to supplement treatment of a wide range of conditions. It is particularly popular for pain management, spasticity, anorexia, vomiting and depression.
Dr. Reddy's and MediCane have also signed an agreement for the co-funding of a Phase II clinical trial for a cannabis product aimed at symptom relief of Behavioral and Psychological Symptoms of Dementia (BPSD). BPSD refers to the spectrum of commonly observed non-cognitive and non-neurological symptoms of dementia, such as agitation, aggression, psychosis, depression, and apathy.
Dr. Reddy's will hold exclusive sales and marketing rights for the product in Europe (except Russia and CIS countries) upon completion of the trial, which is expected to begin during the second half of 2022.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.